EDP Sciences logo
Submit your paper
Search
Menu
Home All issues Volume 24 / No 2 (June 2018) J Oral Med Oral Surg, 24 2 (2018) 72-75 References
Open Access
Issue
J Oral Med Oral Surg
Volume 24, Number 2, June 2018
Page(s) 72 - 75
Section Cas clinique et revue de la littérature / Up-to date review and case report
DOI https://doi.org/10.1051/mbcb/2017033
Published online 29 June 2018
  1. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, Lacouture ME. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012;67:1025–1039. [CrossRef] [PubMed] [Google Scholar]
  2. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 2010;70:1059–1078. [CrossRef] [PubMed] [Google Scholar]
  3. Cartwright TH. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:155–166. [CrossRef] [PubMed] [Google Scholar]
  4. Karthaus M, Hofheinz R-D, Mineur L, Letocha H, Greil R, Thaler J, et al. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer 2016;115:1215–1222. [CrossRef] [PubMed] [Google Scholar]
  5. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res 2015;21:5469–5479. [CrossRef] [PubMed] [Google Scholar]
  6. McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, Panasci L, Melnychuk D, Batist G, Kavan P. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. Clin Colorectal Cancer 2016;15:135–140. [CrossRef] [PubMed] [Google Scholar]
  7. Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol 2015;12:607–19. [CrossRef] [Google Scholar]
  8. Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657–670. [CrossRef] [PubMed] [Google Scholar]
  9. Sibaud V, Delord J-P, Kidney C, Gangloff D, Garrido-Stowhas I. Dermatological toxicity of new targeted anti-cancer therapies used in oncodermatology. Ann Chir Plast Esthét. 2012;57:106–113. [CrossRef] [Google Scholar]
  10. Bergman H, Walton T, Del Bel R, Seki JT, Rafii A, Xu W, Koren G, Shear N, Kryzanawska MK, Howell D, Liu G. Managing skin toxicities related to panitumumab. J Am Acad Dermatol 2014;71:754–759. [CrossRef] [PubMed] [Google Scholar]
  11. D’Alessio A, Cecchini S, Di Mauro D, Geroli L, Villa S, Quadri A, Resta D, Fortugno C. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report. Tumori J. 2016;102(Suppl. 2):65–68. [CrossRef] [Google Scholar]
  12. Sibaud V, Boralevi F, Vigarios E, Fricain J-C. Endobuccal toxicity of targeted anti-cancer therapies. Ann Dermatol Venereology 2014;141:354–363. [CrossRef] [PubMed] [Google Scholar]
  13. Sibaud V, Vigarios E. Oral toxicities of targeted anti-cancer therapies. Oral Medicine Chir Oral 2015;21:149–155. [Google Scholar]
  14. Funakoshi T, Suzuki M, Tamura K. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis. Cancer Treat Rev 2014;40:1221–1229. [CrossRef] [PubMed] [Google Scholar]
  15. Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 2011;65:624–635. [CrossRef] [PubMed] [Google Scholar]
  16. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Krsi MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010;18:509–522. [CrossRef] [PubMed] [Google Scholar]
  17. Jaka A, Gutiérrez-Rivera A, López-Pestaña A, del Alcázar E, Zubizarreta J, Vildosola S, Arrequi MA, Sarasqueta C, Lobo C, Tuneu A. Predictors of tumor response to cetuximab and panitumumab in 116 patients and a review of approaches to managing skin toxicity. Actas Dermo-Sifiliográficas Engl Ed. 2015;106:483–492. [CrossRef] [Google Scholar]
  18. Petrelli F, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, Barni S. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol 2016;175:1166–1174. [CrossRef] [PubMed] [Google Scholar]
  19. Bennett L, Zhao Z, Barber B, Zhou X, Peeters M, Zhang J, Xu F, Weiezorek J, Douillard JY. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer 2011;105:1495–1502. [CrossRef] [PubMed] [Google Scholar]
  20. Koukakis R, Gatta F, Hechmati G, Siena S. Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials. Qual Life Res 2016;25:2645–2656. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.